Which has stronger earnings & valuation, ARAV or AIMDW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aravive N/A N/A N/A -$0.90 N/A Ainos $18.11K N/A N/A N/A N/A

Is ARAV or AIMDW more profitable?

Company Net Margins Return on Equity Return on Assets Aravive N/A N/A N/A Ainos N/A N/A N/A

Which has preferable earnings and valuation, ARAV or ALVOW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aravive N/A N/A N/A -$0.90 N/A Alvotech $559.42M N/A N/A N/A N/A

Is ARAV or ALVOW more profitable?

Company Net Margins Return on Equity Return on Assets Aravive N/A N/A N/A Alvotech N/A N/A N/A

Which has higher valuation & earnings, ACABW or ARAV?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atlantic Coastal Acquisition Corp. II N/A N/A N/A N/A N/A Aravive N/A N/A N/A -$0.90 N/A

Is ACABW or ARAV more profitable?

Company Net Margins Return on Equity Return on Assets Atlantic Coastal Acquisition Corp. II N/A N/A N/A Aravive N/A N/A N/A

Which has stronger valuation and earnings, BFRIW or ARAV?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biofrontera $43.20M N/A N/A N/A N/A Aravive N/A N/A N/A -$0.90 N/A

Is BFRIW or ARAV more profitable?

Company Net Margins Return on Equity Return on Assets Biofrontera N/A N/A N/A Aravive N/A N/A N/A

Which has stronger valuation and earnings, CELUW or ARAV?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celularity $26.55M N/A N/A N/A N/A Aravive N/A N/A N/A -$0.90 N/A

Is CELUW or ARAV more profitable?

Company Net Margins Return on Equity Return on Assets Celularity N/A N/A N/A Aravive N/A N/A N/A

Aravive (ARAV) Competitors

$0.04 0.00 (0.00%)

As of 07/15/2026

Compare

ARAV vs. AIMDW, ALVOW, ACABW, BFRIW, and CELUW

Should you buy Aravive stock or one of its competitors? MarketBeat compares Aravive with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aravive include Ainos (AIMDW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), Biofrontera (BFRIW), and Celularity (CELUW). These companies are all part of the "pharmaceutical products" industry.

How does Aravive compare to Ainos?

Aravive (NASDAQ:ARAV) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
Ainos	N/A	N/A	N/A

In the previous week, Ainos had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Ainos and 0 mentions for Aravive. Ainos' average media sentiment score of 1.74 beat Aravive's score of 0.00 indicating that Ainos is being referred to more favorably in the news media.

Company	Overall Sentiment
Aravive	Neutral
Ainos	Very Positive

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	N/A	N/A	N/A	-$0.90	N/A
Ainos	$18.11K	N/A	N/A	N/A	N/A

Summary

Ainos beats Aravive on 3 of the 5 factors compared between the two stocks.

How does Aravive compare to Alvotech?

Aravive (NASDAQ:ARAV) and Alvotech (NASDAQ:ALVOW) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	N/A	N/A	N/A	-$0.90	N/A
Alvotech	$559.42M	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
Alvotech	N/A	N/A	N/A

In the previous week, Alvotech had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Alvotech and 0 mentions for Aravive. Alvotech's average media sentiment score of 1.89 beat Aravive's score of 0.00 indicating that Alvotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Aravive	Neutral
Alvotech	Very Positive

Summary

Alvotech beats Aravive on 3 of the 5 factors compared between the two stocks.

How does Aravive compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and Aravive (NASDAQ:ARAV) are both pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Company	Net Margins	Return on Equity	Return on Assets
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A
Aravive	N/A	N/A	N/A

In the previous week, Atlantic Coastal Acquisition Corp. II's average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company	Overall Sentiment
Atlantic Coastal Acquisition Corp. II	Neutral
Aravive	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A
Aravive	N/A	N/A	N/A	-$0.90	N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Aravive beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does Aravive compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	N/A	N/A	N/A
Aravive	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$43.20M	N/A	N/A	N/A	N/A
Aravive	N/A	N/A	N/A	-$0.90	N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Biofrontera had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for Aravive. Biofrontera's average media sentiment score of 1.87 beat Aravive's score of 0.00 indicating that Biofrontera is being referred to more favorably in the media.

Company	Overall Sentiment
Biofrontera	Very Positive
Aravive	Neutral

Summary

Biofrontera beats Aravive on 3 of the 5 factors compared between the two stocks.

How does Aravive compare to Celularity?

Celularity (NASDAQ:CELUW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	N/A	N/A	N/A	N/A
Aravive	N/A	N/A	N/A	-$0.90	N/A

In the previous week, Celularity had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Celularity and 0 mentions for Aravive. Celularity's average media sentiment score of 1.89 beat Aravive's score of 0.00 indicating that Celularity is being referred to more favorably in the media.

Company	Overall Sentiment
Celularity	Very Positive
Aravive	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Celularity	N/A	N/A	N/A
Aravive	N/A	N/A	N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Celularity beats Aravive on 3 of the 5 factors compared between the two stocks.

Get Aravive News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARAV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARAV vs. The Competition

Export

Metric	Aravive	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	N/A	$3.67B	$6.96B	$12.67B
Dividend Yield	N/A	2.20%	2.68%	8.87%
P/E Ratio	-0.04	21.07	27.20	24.05
Price / Sales	N/A	300.81	578.13	112.08
Price / Cash	N/A	146.26	49.25	59.89
Price / Book	N/A	8.39	10.74	6.23
Net Income	N/A	$23.83M	$3.59B	$331.94M
7 Day Performance	N/A	-3.70%	-1.92%	-1.65%
1 Month Performance	N/A	3.04%	2.23%	-1.03%
1 Year Performance	N/A	42.73%	23.82%	17.10%

Aravive Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARAV Aravive	N/A	$0.04 flat	N/A	N/A	$0.00	N/A	N/A	20	High Trading Volume
AIMDW Ainos	N/A	$0.15 -3.3%	N/A	-47.1%	$0.00	$18.11K	N/A	40	Gap Down
ALVOW Alvotech	N/A	$0.17 flat	N/A	-90.3%	$0.00	$559.42M	N/A	4
ACABW Atlantic Coastal Acquisition Corp. II	N/A	$0.00 +4.0%	N/A	N/A	$0.00	N/A	N/A	15	Gap Up
BFRIW Biofrontera	N/A	$0.03 -5.9%	N/A	-70.6%	$0.00	$43.20M	N/A	70	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARAV) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aravive (ARAV) Competitors